This article was originally published in The Gray Sheet
Executive SummaryPhase III clinical trials for its intraocular Implantable Contact Lens for the treatment of myopia will begin following FDA go ahead. Staar, which so far has tested the ICL in 80 eyes, may now implant another 278 IOLs, while increasing the number of sites to 15, the company says. The Monrovia, California-based firm also may expand its study to treat patients with as little as -3 diopters of refractive error and reduce the waiting period for patients to receive an IOL in the second eye to 45 days from six months
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.